Clincosm LogoSign in Get a demo

rTMS for Relieving Chronic OA Pain

Sponsor
Northwestern University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05097729
Collaborator
(none)
35
Enrollment
1
Location
3
Arms
13.5
Anticipated Duration (Months)
2.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study the investigators aim to examine the effects of Transcranial Magnetic Stimulation (TMS) on hippocampal network connectivity and pain levels in individuals with pain due to knee osteoarthritis.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Magnetic Stimulation
 N/A

Detailed Description

Osteoarthritis (OA) pain is one of the most prevalent causes of chronic pain worldwide. Symptoms can last from months to a lifetime, severely impacting patients' quality of life. New strategies - including non-invasive brain stimulation techniques - have shown promise for sustained pain relief, yet evidence on their reliability and efficacy is limited. Apkarian et. al have previously shown that the dorsal hippocampus plays a central role in pain analgesia; thus, the study aim is to test whether non-invasively enhancing dorsal hippocampus activity is a useful new strategy for pain relief in knee OA patients. This study will recruit 35 patients with chronic OA pain for > 6 months. Each participant will receive 3 rounds of different treatment modalities in a cross-over manner. Each treatment modality will consist of 5 daily consecutive rTMS sessions followed by a 2-weeks wash-out period. Questionnaires will be completed prior to and following each intervention, and after each treatment round. Participants will be trained to use a pain electronic application (smartphone-based tool to rate pain intensity and mood on NRS scales, as well as indicate rescue medication use, developed in our lab). They will be asked to use this application for 7-10 days prior to the first round of intervention and during the study duration.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
35 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
All participants will receive all the 3 modalities of stimulation in a randomized order. Each round is composed by 5 daily sessions of stimulation. Participants will have a second MRI only after Modality one (hippocampal).All participants will receive all the 3 modalities of stimulation in a randomized order. Each round is composed by 5 daily sessions of stimulation. Participants will have a second MRI only after Modality one (hippocampal).
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcranial Magnetic Stimulation to Enhance Cortical Hippocampal Functional Connectivity as a Novel Means for Relieving Chronic OA Pain
Actual Study Start Date :
Nov 15, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stimulation Modality 1

Repetitive TMS will be applied at 100% resting motor threshold intensity to a region of interest located in the parietal cortex, that will be determined based on its connectivity with the hippocampus.

Device: Transcranial Magnetic Stimulation
The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
Other Names:
  • TMS

    		•
    Sham Comparator: Stimulation Modality 2

    Parameters will be identical to the modality 1, except that the coil will be flipped over.

    Device: Transcranial Magnetic Stimulation
    The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
    Other Names:
  • TMS

    		•
    Active Comparator: Stimulation Modality 3

    The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.

    Device: Transcranial Magnetic Stimulation
    The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
    Other Names:
  • TMS

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Pain ratings (Numeric Rating Scale) [Pain ratings immediately after each rTMS modality and effects after the end of stimulation round (1 week).]

      The primary efficacy outcomes are the effects of the rTMS modalities on pain app ratings.

    Secondary Outcome Measures

    1. Pain trajectories [1 to 12 weeks (end of the study)]

      Individual pain trajectories will be analyzed to assess rTMS effects with greater temporal granularity.

    2. Brain biomarkers and psychological indicators of rTMS effects and pain relief [1 to 12 weeks (end of the study)]

      Test for objective mechanistic brain correlates (using functional magnetic resonance imaging - fMRI) for treatment efficacy. Specific regions of interest (ROI) involved in the hippocampal network will be studied.

    3. Adverse events [1 to 12 weeks (end of the study)]

      Incidence of adverse events will be reported for after each rTMS session.The frequency and severity of adverse effects will be compared between each rTMS modality.

    4. Global impression of change [1 to 12 weeks - after each rTMS round.]

      Global impression of change (PGIC): this questionnaire reflects a patient's belief about the efficacy of treatment. Although widely used in chronic pain clinical trials, PGIC's validity has not been formally assessed. PGIC is a 7 point scale depicting a patient's rating of overall improvement.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • ≥ 6 months of knee pain on a daily basis;

    • male or female with no racial or ethnic restrictions;

    • 18 to 75 years old;

    • average knee pain intensity > 4/10 at study entry;

    • must be able to read, understand, and sign consent form;

    • generally healthy.

    • able to use the PainApp

    Exclusion Criteria:

    • rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures,

    • Chronic neurologic conditions, e.g., Parkinson's

    • other severe medical diseases;

    • pregnancy;

    • positive urinary screen for any recreational drugs,

    • opioids use;

    • use of anticoagulants (low dose ASA allowed);

    • history of gastric ulcer; renal insufficiency or congestive heart failure,

    • contraindication to MRI,

    • contraindication to TMS; including history of seizure/epilepsy*

    • Any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk;

    • In the judgment of the investigator, unable or unwilling to follow protocol and instructions.

    • Diagnosis of major depression.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Northwestern University Chicago Illinois United States 60611

    Sponsors and Collaborators

    • Northwestern University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Apkar Apkarian, Director Center for Translational Pain Research, Director Center of Excellence for Chronic Pain and Drug Abuse Research, Professor of Neuroscience, Anesthesia, PM&R, Northwestern University
    ClinicalTrials.gov Identifier:
    NCT05097729
    Other Study ID Numbers:
    • STU00214446
    First Posted:
    Oct 28, 2021
    Last Update Posted:
    Jan 5, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:
    Osteoarthritis
    Osteoarthritis, Knee
    Chronic Pain

    Study Results

    No Results Posted as of Jan 5, 2022